Specialist Dr. Sinemis Celik

Academic Title :

Specialist Dr.

Department	Work location
Cancer Treatment Department	Medical Park İstanbul Onkoloji

Dr. Sinemis Celik is a Medical Oncology specialist currently practicing at Medical Park Istanbul Oncology Hospital. She brings over 15 years of clinical and academic experience, having served as a teaching staff member at Pamukkale University Faculty of Medicine and as Assistant Professor and Chair of the Education Committee at Istanbul Okan University Hospital. Her key areas of expertise include breast, gastrointestinal, lung, head and neck, and gynecologic cancers, and she holds memberships in leading international societies such as ESMO and ASCO.

Education and Academic Qualifications

Pamukkale University Faculty of Medicine
Supervised Master's Thesis: Evaluation of the Clinical, Pathological, and Prognostic Features and Treatment Outcomes of Non-Hodgkin Lymphoma Cases

Areas of Interest

Breast Cancer
Gastrointestinal System Cancers
Lung Cancer
Head and Neck Cancers
Gynecologic Cancers
Bladder, Prostate, and Urinary Tract Cancers
Brain Cancer
Connective Tissue and Soft Tissue Cancers

Work Experience

2005 – 2011: Teaching Staff Member (Lecturer), Department of Internal Medicine, Pamukkale University Faculty of Medicine
2011: Specialist Physician – Mandatory State Service in Internal Medicine, Hakkari State Hospital (3 months)
2011 – 2014: Medical Oncology Subspecialty Residency, Medical Oncology Clinic, Dr. Lutfi Kirdar Kartal Training and Research Hospital
2014 – 2017: Medical Oncology Specialist, Sultan I. Murat State Hospital, Edirne
2017: Assistant Professor of Medical Oncology & Chair of the Education Committee, Istanbul Okan University Hospital
Currently: Medical Park Istanbul Oncology Hospital

Professional Affiliations & Memberships

Turkish Society of Medical Oncology
European Society for Medical Oncology (ESMO)
American Society of Clinical Oncology (ASCO)
Immuno-Oncology Society
Turkish Medical Association

Research & Publications

Tonyali O, Coskun U, Yuksel S, et al. Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab. Breast. 2016 Feb;25:22-6.
Dinc NS, Aydin K, Odabas H, et al. Pretreatment PET/CT Standardized Uptake Values Play a Role in Predicting Response to Treatment and Survival (source text truncated).

Visits : 38